Journal of endocrinological investigation · 2025
Results for LINAC-based radiosurgery or fractionated stereotactic radiotherapy for corticotropic pituitary tumors: a single-center retrospective cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mauro Geovanne Pedro, Da Róz Leila Maria, de Carvalho Gico Vinicius, Weltman Eduardo, de Souza Evandro César, Glezer Andrea, Machado Marcio Carlos, Carlotti Carlos Gilberto, Villar Rosangela Correa
Аннотация
BACKGROUND: Radiotherapy (RT) plays an important role in the treatment of persistent or recurrent Cushing disease (CD) after primary surgery. We assessed the results for RT using a linear accelerator based (LINAC) stereotactic technique. Primary objectives were progression-free survival (PFS) and time to hormonal disease control (THC).
METHODS: Single-center retrospective cohort in a tertiary, academic hospital assessed between 2008 and 2023.
RESULTS: Fifty-nine patients (59) patients were assessed. Mean age was 41.9 years (range: 15 to 72 years). Most were female (79.7%). Median lesion size at first visit was 1.49 cm (range: 0.3 to 5.2 cm). Patients were either treated with fractionated RT (50.8%) or single-fraction radiosurgery (SRS). Cabergoline was used prior (49.2%) and concurrently to RT (38.9%). Ketoconazole during SRT was also largely used (30.5%). Median follow-up was 69.9 months. There were no reported deaths. Median PFS was not reached, mean was 78.5 months. Disease control was reported in 94.9% of patients. Only 3 (5.1%) acquired new hormonal deficits. Univariate analysis showed that no variable impacted either PFS or tumor response. Criteria for hormonal remission at 12 months were reached in 33.9%. Median THC was 37.1 months (interquartile interval 25% 8.2 months to 75% 153.5 months). There were two new cardiac events during follow-up and new Cushing stigmata arise on two patients (3.3%).
CONCLUSION: We achieved good results for LINAC-based RT in this large, single center cohort with high tumor control. Among patients with CD treatment options impacted neither PFS nor cure rate in this study.
METHODS: Single-center retrospective cohort in a tertiary, academic hospital assessed between 2008 and 2023.
RESULTS: Fifty-nine patients (59) patients were assessed. Mean age was 41.9 years (range: 15 to 72 years). Most were female (79.7%). Median lesion size at first visit was 1.49 cm (range: 0.3 to 5.2 cm). Patients were either treated with fractionated RT (50.8%) or single-fraction radiosurgery (SRS). Cabergoline was used prior (49.2%) and concurrently to RT (38.9%). Ketoconazole during SRT was also largely used (30.5%). Median follow-up was 69.9 months. There were no reported deaths. Median PFS was not reached, mean was 78.5 months. Disease control was reported in 94.9% of patients. Only 3 (5.1%) acquired new hormonal deficits. Univariate analysis showed that no variable impacted either PFS or tumor response. Criteria for hormonal remission at 12 months were reached in 33.9%. Median THC was 37.1 months (interquartile interval 25% 8.2 months to 75% 153.5 months). There were two new cardiac events during follow-up and new Cushing stigmata arise on two patients (3.3%).
CONCLUSION: We achieved good results for LINAC-based RT in this large, single center cohort with high tumor control. Among patients with CD treatment options impacted neither PFS nor cure rate in this study.